Previous 10 | Next 10 |
Summary Leveraged ETFs behavior is neither intuitive nor predictable. Below is a dashboard with 22 of them, including SPUU. LABD is the worst of the list. Focus on SPUU: drift history and comparison with UPRO. The Direxion Daily S&P 500 Bull 2X Shares ETF ( ...
Summary Leveraged ETFs have a non-linear behavior. Biotechnology ETFs LABU and LABD show very large drifts. Lessons of SPXS history. The Direxion Daily S&P 500 Bear 3X Shares ETF ( SPXS ) is one of the most popular instruments to short the broad market for tr...
Summary TAMS for Non-Alcoholic Steatohepatitis NASH after topline PH2a results and what it could mean to Cytodyn long term investors. Wall Street modeling of non-revenue generating biotechs. Headwinds and risks involved. Overview CytoDyn Inc. (CYDY) is a Vanc...
Summary Toripalimab approval will be decided for Coherus at the end of December. Cimerli approval has pushed up the stock. However, the tori PDUFA is the major catalytic event here. It is interesting to see that despite its foray into original R&D through a Chine...
Alnylam is rapidly becoming the leader in ATTR through its successful therapy, patisiran. Intellia has presented data showing even deeper reductions in TTR. Though early Intellia has the potential to show better clinical outcomes in patients with ATTR. For years, patient...
Gainers: MicroSectors Gold Miners -3X Inverse Leveraged ETNs ( GDXD ) +26% . Direxion Daily S&P Biotech Bear 3x Shares ETF ( LABD ) +23% . Direxion Daily Junior Gold Miners Index Bear 3x Shares ETF ( JDST ) +20% . ProShares UltraShort Silver ( ...
ImmunoGen announced that it will receive the FDA decision for mirvetuximab on November 28th. The deal with Oxford BioTechnologies will support further growth. ImmunoGen remains robust from a financial point of view. Two weeks ago, the leading biotech company ImmunoGen, I...
Results for both studies from the DISSOLVE phase 3 program, using SEL-212 for the treatment of patients with chronic refractory gout, are expected in Q1 of 2023. Potential to restore immune tolerance and target underlying cause of patients with primary biliary cirrhosis with use of Im...
Drift review of 22 leveraged ETFs. ZSL and LABU show significant monthly decay. LABD and SOXS have the worst 12-month drifts in my list. Historical decay of SDS is close to zero on average, but it may hurt on limited periods of time. The ProShares UltraShort S&P ...
After the FDA provided an update on the agency's response to the monkeypox outbreak on July 29th, investors misunderstood the FDA's statements, and the stock sold off 33% and shortly reverted. SIGA's monkeypox treatment TPOXX is already approved in the U.S., EU, and Canada for smallpo...
News, Short Squeeze, Breakout and More Instantly...
Direxion Daily S&P Biotech Bear 3X Shares Company Name:
LABD Stock Symbol:
NYSE Market:
2024-06-01 07:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-22 08:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-12 22:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...